NASDAQ:CDXC

ChromaDex Competitors

$8.20
-0.33 (-3.87 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$8.17
Now: $8.20
$8.54
50-Day Range
$8.53
MA: $10.75
$18.74
52-Week Range
$3.41
Now: $8.20
$23.66
Volume823,583 shs
Average Volume3.37 million shs
Market Capitalization$547.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49

Competitors

ChromaDex (NASDAQ:CDXC) Vs. USNA, ACB, SNDL, HEXO, MDWD, and NAII

Should you be buying CDXC stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to ChromaDex, including USANA Health Sciences (USNA), Aurora Cannabis (ACB), Sundial Growers (SNDL), HEXO (HEXO), MediWound (MDWD), and Natural Alternatives International (NAII).

ChromaDex (NASDAQ:CDXC) and USANA Health Sciences (NYSE:USNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

24.7% of ChromaDex shares are owned by institutional investors. Comparatively, 54.1% of USANA Health Sciences shares are owned by institutional investors. 12.9% of ChromaDex shares are owned by company insiders. Comparatively, 45.4% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ChromaDex and USANA Health Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChromaDex$46.29 million11.83$-32,150,000.00($0.52)-15.77
USANA Health Sciences$1.06 billion1.92$100.53 million$4.4122.42

USANA Health Sciences has higher revenue and earnings than ChromaDex. ChromaDex is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for ChromaDex and USANA Health Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChromaDex00303.00
USANA Health Sciences00203.00

ChromaDex currently has a consensus target price of $14.3333, indicating a potential upside of 74.80%. USANA Health Sciences has a consensus target price of $126.00, indicating a potential upside of 27.41%. Given ChromaDex's higher possible upside, equities analysts clearly believe ChromaDex is more favorable than USANA Health Sciences.

Profitability

This table compares ChromaDex and USANA Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChromaDex-39.86%-100.14%-50.35%
USANA Health Sciences10.57%32.91%22.26%

Volatility and Risk

ChromaDex has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Summary

USANA Health Sciences beats ChromaDex on 9 of the 13 factors compared between the two stocks.

ChromaDex (NASDAQ:CDXC) and Aurora Cannabis (NYSE:ACB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

24.7% of ChromaDex shares are owned by institutional investors. Comparatively, 11.9% of Aurora Cannabis shares are owned by institutional investors. 12.9% of ChromaDex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ChromaDex and Aurora Cannabis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChromaDex$46.29 million11.83$-32,150,000.00($0.52)-15.77
Aurora Cannabis$207.89 million7.50$-2,468,190,000.00($2.86)-2.76

ChromaDex has higher earnings, but lower revenue than Aurora Cannabis. ChromaDex is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for ChromaDex and Aurora Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChromaDex00303.00
Aurora Cannabis69001.60

ChromaDex currently has a consensus target price of $14.3333, indicating a potential upside of 74.80%. Aurora Cannabis has a consensus target price of $10.9264, indicating a potential upside of 38.66%. Given ChromaDex's stronger consensus rating and higher possible upside, equities analysts clearly believe ChromaDex is more favorable than Aurora Cannabis.

Profitability

This table compares ChromaDex and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChromaDex-39.86%-100.14%-50.35%
Aurora Cannabis-1,238.94%-16.32%-13.12%

Volatility and Risk

ChromaDex has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.44, indicating that its stock price is 244% more volatile than the S&P 500.

Summary

ChromaDex beats Aurora Cannabis on 9 of the 14 factors compared between the two stocks.

ChromaDex (NASDAQ:CDXC) and Sundial Growers (NASDAQ:SNDL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

24.7% of ChromaDex shares are owned by institutional investors. Comparatively, 3.3% of Sundial Growers shares are owned by institutional investors. 12.9% of ChromaDex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ChromaDex and Sundial Growers' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChromaDex$46.29 million11.83$-32,150,000.00($0.52)-15.77
Sundial Growers$75.86 million18.54$-204,570,000.00($3.17)-0.27

ChromaDex has higher earnings, but lower revenue than Sundial Growers. ChromaDex is trading at a lower price-to-earnings ratio than Sundial Growers, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for ChromaDex and Sundial Growers, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChromaDex00303.00
Sundial Growers32001.40

ChromaDex currently has a consensus target price of $14.3333, indicating a potential upside of 74.80%. Sundial Growers has a consensus target price of $0.7333, indicating a potential downside of 13.42%. Given ChromaDex's stronger consensus rating and higher possible upside, equities analysts clearly believe ChromaDex is more favorable than Sundial Growers.

Profitability

This table compares ChromaDex and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChromaDex-39.86%-100.14%-50.35%
Sundial Growers-415.89%-187.67%-72.67%

Volatility and Risk

ChromaDex has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, indicating that its stock price is 601% more volatile than the S&P 500.

Summary

ChromaDex beats Sundial Growers on 10 of the 14 factors compared between the two stocks.

ChromaDex (NASDAQ:CDXC) and HEXO (NYSE:HEXO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

24.7% of ChromaDex shares are owned by institutional investors. Comparatively, 35.3% of HEXO shares are owned by institutional investors. 12.9% of ChromaDex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ChromaDex and HEXO's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChromaDex$46.29 million11.83$-32,150,000.00($0.52)-15.77
HEXO$60.46 million11.18$-406,370,000.00($0.96)-5.75

ChromaDex has higher earnings, but lower revenue than HEXO. ChromaDex is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for ChromaDex and HEXO, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChromaDex00303.00
HEXO35402.08

ChromaDex currently has a consensus target price of $14.3333, indicating a potential upside of 74.80%. HEXO has a consensus target price of $4.1750, indicating a potential downside of 24.37%. Given ChromaDex's stronger consensus rating and higher possible upside, equities analysts clearly believe ChromaDex is more favorable than HEXO.

Profitability

This table compares ChromaDex and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChromaDex-39.86%-100.14%-50.35%
HEXO-517.61%-13.15%-10.35%

Volatility and Risk

ChromaDex has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, HEXO has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Summary

ChromaDex beats HEXO on 8 of the 14 factors compared between the two stocks.

ChromaDex (NASDAQ:CDXC) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Earnings and Valuation

This table compares ChromaDex and MediWound's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChromaDex$46.29 million11.83$-32,150,000.00($0.52)-15.77
MediWound$31.79 million4.32$4.95 million$0.0863.00

MediWound has lower revenue, but higher earnings than ChromaDex. ChromaDex is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ChromaDex has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Insider and Institutional Ownership

24.7% of ChromaDex shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. 12.9% of ChromaDex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares ChromaDex and MediWound's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChromaDex-39.86%-100.14%-50.35%
MediWound-53.12%-94.63%-29.86%

Analyst Ratings

This is a summary of current recommendations for ChromaDex and MediWound, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChromaDex00303.00
MediWound00403.00

ChromaDex currently has a consensus target price of $14.3333, indicating a potential upside of 74.80%. MediWound has a consensus target price of $7.50, indicating a potential upside of 48.81%. Given ChromaDex's higher possible upside, equities analysts clearly believe ChromaDex is more favorable than MediWound.

Summary

MediWound beats ChromaDex on 7 of the 13 factors compared between the two stocks.

ChromaDex (NASDAQ:CDXC) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares ChromaDex and Natural Alternatives International's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChromaDex$46.29 million11.83$-32,150,000.00($0.52)-15.77
Natural Alternatives International$118.88 million0.97$-1,640,000.00N/AN/A

Natural Alternatives International has higher revenue and earnings than ChromaDex.

Risk & Volatility

ChromaDex has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

Institutional and Insider Ownership

24.7% of ChromaDex shares are owned by institutional investors. Comparatively, 31.8% of Natural Alternatives International shares are owned by institutional investors. 12.9% of ChromaDex shares are owned by company insiders. Comparatively, 26.4% of Natural Alternatives International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares ChromaDex and Natural Alternatives International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChromaDex-39.86%-100.14%-50.35%
Natural Alternatives International0.40%0.71%0.43%

Analyst Recommendations

This is a breakdown of current ratings for ChromaDex and Natural Alternatives International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChromaDex00303.00
Natural Alternatives International0000N/A

ChromaDex currently has a consensus target price of $14.3333, indicating a potential upside of 74.80%. Given ChromaDex's higher possible upside, equities research analysts clearly believe ChromaDex is more favorable than Natural Alternatives International.

Summary

Natural Alternatives International beats ChromaDex on 8 of the 12 factors compared between the two stocks.


ChromaDex Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$98.89-2.6%$2.04 billion$1.06 billion18.31Analyst Downgrade
Aurora Cannabis logo
ACB
Aurora Cannabis
1.5$7.88-1.1%$1.56 billion$207.89 million-0.32Analyst Downgrade
Sundial Growers logo
SNDL
Sundial Growers
1.0$0.85-1.2%$1.41 billion$75.86 million-0.33Analyst Upgrade
Gap Up
HEXO logo
HEXO
HEXO
1.1$5.52-3.3%$676.12 million$60.46 million-1.13Gap Up
MediWound logo
MDWD
MediWound
1.4$5.04-2.0%$137.27 million$31.79 million-12.60Decrease in Short Interest
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$18.20-6.3%$115.72 million$118.88 million227.53High Trading Volume
Increase in Short Interest
Gap Up
HAPP
Happiness Biotech Group
0.6$1.84-0.5%$47.53 million$65.06 million0.00Increase in Short Interest
News Coverage
Mannatech logo
MTEX
Mannatech
1.3$19.13-2.4%$39.58 million$157.73 million5.89Gap Down
FSD Pharma logo
HUGE
FSD Pharma
0.3$1.56-1.9%$29.89 million$190,000.00-0.35Increase in Short Interest
News Coverage
CYAN
Cyanotech
0.6$3.14-1.6%$19.15 million$31.90 million31.40
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.